問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

張雅菁

Recruiting

List

22Cases

2025-03-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2022-06-10 - 2023-09-29

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-02-03 - 2022-12-16

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-01-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2025-11-03 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2023-02-01 - 2024-08-08

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2025-06-30 - 2027-07-28

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2025-09-30 - 2027-06-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2024-01-01 - 2027-12-31

Phase III

Active
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

  • Condition/Disease

    Moderate to Severe Plaque Psoriasis

  • Test Drug

    N/A

Participate Sites
7Sites

Recruiting7Sites

2019-12-01 - 2022-12-31

Phase IV

A Phase 3b, Multicenter, Interventional, Open-label Study of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Have a Suboptimal Response to Secukinumab or Ixekizumab and Are Switched to Risankizumab

  • Condition/Disease

    Moderate to Severe Plaque Psoriasis

  • Test Drug

    Risankizumab Risankizumab

Participate Sites
4Sites

Recruiting4Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB